Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Public Forum Previews Hill Debate; Safety, Critical Path Emphasized

Executive Summary

With the Prescription Drug User Fee Act moving towards reauthorization, a public forum on Feb. 16 hinted at how that debate may play out on Capitol Hill. At the meeting sponsored by FDA, outside groups voiced concerns about the agency's proposal for the PDUFA program and made their case for how FDA should organize and spend requested funding

You may also be interested in...



PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill

The role of drug manufacturers in negotiating how FDA spends prescription drug user fees would be diminished under a draft user fee reauthorization bill prepared for markup in the House Energy and Commerce Committee's Health Subcommittee

PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill

The role of drug manufacturers in negotiating how FDA spends prescription drug user fees would be diminished under a draft user fee reauthorization bill prepared for markup in the House Energy and Commerce Committee's Health Subcommittee

DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan

FDA expects to charge companies $83,000 per advertisement under a pre-review program included as part of the agency's proposal for renewal of the prescription drug user fee program

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel